Doris Phelps1, Kathryn Bondra2, Star Seum2, Christopher Chronowski2, Justin Leasure2, Raushan T Kurmasheva1, Steven Middleton3, Dian Wang4, Xiaokui Mo5, Peter J Houghton1. 1. Center for Childhood Cancer & Blood Diseases, Nationwide Children's Hospital, Columbus, Ohio, 43205. 2. Wexner Medical Center at The Ohio State University, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, Columbus, Ohio. 3. Hoffmann-La Roche, Inc., New York. 4. Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois. 5. Center for Biostatistics, The Ohio State University, Columbus, Ohio.
Abstract
BACKGROUND: Curative therapy for childhood sarcoma presents challenges when complete resection is not possible. Ionizing radiation (XRT) is used as a standard modality at diagnosis or recurrence for childhood sarcoma; however, local recurrence is still problematic. Most childhood sarcomas are TP53 wild type at diagnosis, although approximately 5-10% have MDM2 amplification or overexpression. PROCEDURES: The MDM2 inhibitor, RG7388, was examined alone or in combination with XRT (20Gy given in 2 Gy daily fractions) to immune-deficient mice bearing Rh18 (embryonal) or a total of 30 Gy in 2 Gy fractions to mice bearing Rh30 (alveolar) rhabdomyosarcoma xenografts. RG7388 was administered by oral gavage using two schedules (daily ×5; schedule 1 or once weekly; schedule 2). TP53-responsive gene products (p21, PUMA, DDB2, and MIC1) as well as markers of apoptosis were analyzed. RESULTS: RG7388 showed no significant single agent antitumor activity. Twenty Grays XRT induced complete regressions (CR) of Rh18 with 100 percent tumor regrowth by week 7, but no tumor regrowth at 20 weeks when combined with RG7388. RG7388 enhanced time to recurrence combined with XRT in Rh30 xenografts compared to 30 Gy XRT alone. RG7388 did not enhance XRT-induced local skin toxicity. Combination treatments induced TP53 responsive genes more rapidly and to a greater magnitude than single agent treatments. CONCLUSIONS: RG7388 enhanced the activity of XRT in both rhabdomyosarcoma models without increasing local XRT-induced skin toxicity. Changes in TP53-responsive genes were consistent with the synergistic activity of RG7388 and XRT in the Rh18 model.
BACKGROUND: Curative therapy for childhood sarcoma presents challenges when complete resection is not possible. Ionizing radiation (XRT) is used as a standard modality at diagnosis or recurrence for childhood sarcoma; however, local recurrence is still problematic. Most childhood sarcomas are TP53 wild type at diagnosis, although approximately 5-10% have MDM2 amplification or overexpression. PROCEDURES: The MDM2 inhibitor, RG7388, was examined alone or in combination with XRT (20Gy given in 2 Gy daily fractions) to immune-deficient mice bearing Rh18 (embryonal) or a total of 30 Gy in 2 Gy fractions to mice bearing Rh30 (alveolar) rhabdomyosarcoma xenografts. RG7388 was administered by oral gavage using two schedules (daily ×5; schedule 1 or once weekly; schedule 2). TP53-responsive gene products (p21, PUMA, DDB2, and MIC1) as well as markers of apoptosis were analyzed. RESULTS:RG7388 showed no significant single agent antitumor activity. Twenty Grays XRT induced complete regressions (CR) of Rh18 with 100 percent tumor regrowth by week 7, but no tumor regrowth at 20 weeks when combined with RG7388. RG7388 enhanced time to recurrence combined with XRT in Rh30 xenografts compared to 30 Gy XRT alone. RG7388 did not enhance XRT-induced local skin toxicity. Combination treatments induced TP53 responsive genes more rapidly and to a greater magnitude than single agent treatments. CONCLUSIONS:RG7388 enhanced the activity of XRT in both rhabdomyosarcoma models without increasing local XRT-induced skin toxicity. Changes in TP53-responsive genes were consistent with the synergistic activity of RG7388 and XRT in the Rh18 model.
Authors: Qingjie Ding; Zhuming Zhang; Jin-Jun Liu; Nan Jiang; Jing Zhang; Tina M Ross; Xin-Jie Chu; David Bartkovitz; Frank Podlaski; Cheryl Janson; Christian Tovar; Zoran M Filipovic; Brian Higgins; Kelli Glenn; Kathryn Packman; Lyubomir T Vassilev; Bradford Graves Journal: J Med Chem Date: 2013-07-16 Impact factor: 7.446
Authors: Nikia A Laurie; Stacy L Donovan; Chie-Schin Shih; Jiakun Zhang; Nicholas Mills; Christine Fuller; Amina Teunisse; Suzanne Lam; Yolande Ramos; Adithi Mohan; Dianna Johnson; Matthew Wilson; Carlos Rodriguez-Galindo; Micaela Quarto; Sarah Francoz; Susan M Mendrysa; R Kiplin Guy; Jean-Christophe Marine; Aart G Jochemsen; Michael A Dyer Journal: Nature Date: 2006-11-02 Impact factor: 49.962
Authors: Hernan Carol; C Patrick Reynolds; Min H Kang; Stephen T Keir; John M Maris; Richard Gorlick; E Anders Kolb; Catherine A Billups; Brian Geier; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith; Richard B Lock Journal: Pediatr Blood Cancer Date: 2012-07-02 Impact factor: 3.167
Authors: Hongmei Luo; Caroline Yount; Hainan Lang; Aimin Yang; Ellen C Riemer; Katherine Lyons; Kenneth N Vanek; Gerard A Silvestri; Bradley A Schulte; Gavin Y Wang Journal: Lung Cancer Date: 2013-05-16 Impact factor: 5.705
Authors: Christian Tovar; Bradford Graves; Kathryn Packman; Zoran Filipovic; Brian Higgins; Mingxuan Xia; Christine Tardell; Rosario Garrido; Edmund Lee; Kenneth Kolinsky; Kwong-Him To; Michael Linn; Frank Podlaski; Peter Wovkulich; Binh Vu; Lyubomir T Vassilev Journal: Cancer Res Date: 2013-02-11 Impact factor: 12.701
Authors: Maite Verreault; Charlotte Schmitt; Lauriane Goldwirt; Kristine Pelton; Samer Haidar; Camille Levasseur; Jeremy Guehennec; David Knoff; Marianne Labussière; Yannick Marie; Azra H Ligon; Karima Mokhtari; Khê Hoang-Xuan; Marc Sanson; Brian M Alexander; Patrick Y Wen; Jean-Yves Delattre; Keith L Ligon; Ahmed Idbaih Journal: Clin Cancer Res Date: 2015-10-19 Impact factor: 12.531
Authors: Min H Kang; C Patrick Reynolds; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard Lock; Stephen T Keir; John M Maris; Jianwrong Wu; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2016-05-30 Impact factor: 3.167
Authors: Myrthala Moreno-Smith; Anna Lakoma; Zaowen Chen; Ling Tao; Kathleen A Scorsone; Linda Schild; Kevin Aviles-Padilla; Rana Nikzad; Yankai Zhang; Rikhia Chakraborty; Jan J Molenaar; Sanjeev A Vasudevan; Vivien Sheehan; Eugene S Kim; Silke Paust; Jason M Shohet; Eveline Barbieri Journal: Clin Cancer Res Date: 2017-08-18 Impact factor: 12.531
Authors: Raushan T Kurmasheva; Abhik Bandyopadhyay; Edward Favours; Vanessa Del Pozo; Samson Ghilu; Doris A Phelps; Stephen W Erickson; Cody J Peer; William D Figg; Malcolm A Smith; Peter J Houghton Journal: Pediatr Blood Cancer Date: 2019-05-16 Impact factor: 3.167
Authors: Lindi Chen; Fabio Pastorino; Philip Berry; Jennifer Bonner; Calum Kirk; Katrina M Wood; Huw D Thomas; Yan Zhao; Antonio Daga; Gareth J Veal; John Lunec; David R Newell; Mirco Ponzoni; Deborah A Tweddle Journal: Int J Cancer Date: 2019-01-09 Impact factor: 7.396